Respiree

Remote cardio-pulmonary care platform

Pitch Singapore

▲ 0 votesLaunched May 11, 2026

Visit Website

Daily #5Weekly #3

Respiree builds a cardio-pulmonary remote care platform for continuous monitoring across healthcare settings. The site points to a regulated medtech product, but it still looks enterprise and device-led rather than a strong self-serve Product Hunt launch.

AI Analysis

📝 Summary

Respiree is a regulated medtech cardio-pulmonary remote care platform for continuous patient monitoring across healthcare settings from hospital to home. Core features include wearable sensors for real-time vital data capture, analytics dashboard for providers, and alerts for early intervention. It addresses key pain points like intermittent monitoring, delayed detection of deterioration in chronic conditions (e.g. COPD, heart failure), and high readmission costs. USP is its focus on accurate, continuous cardio-pulmonary metrics in a device-led enterprise solution, delivering value through improved outcomes, reduced hospital stays, and proactive remote care.

📈 Market Timing

Favorable for 2025-2026 due to maturing AI/IoT for remote monitoring, post-pandemic telehealth adoption, aging populations driving chronic cardio-pulmonary disease prevalence, and policies promoting cost-reducing remote care. Regulatory pathways for medtech are established though stringent. Excellent Timing.

✅ Feasibility

Medium feasibility. Technical sensors and AI analytics are achievable but regulated medtech requires extensive clinical validation, FDA/CE approvals adding time and cost. Hardware supply chain and enterprise integration increase operational complexity and capital needs. Scalability is high once approved but team must have strong medtech expertise. Key risks are compliance and development costs.

🎯 Target Market

Primary segments: Hospitals, clinics, and healthcare systems (B2B enterprise sales) in Singapore, US, Europe; secondary are patients with chronic cardio-pulmonary conditions (elderly, 50+). Focus on cardio-pulmonary departments. Estimated market: Large TAM in global remote patient monitoring (> $100B projected by 2026), SAM for cardio-pulmonary subset significant. Core pains: Lack of continuous data leading to reactive care. High willingness to pay for solutions demonstrating ROI via reduced readmissions.

⚔️ Competition

Medium. Direct competitors: 1. Biofourmis (biofourmis.com), 2. Current Health (currenthealth.com acquired by Best Buy), 3. Philips Remote Cardiac Monitoring (philips.com), 4. VitalConnect (vitalconnect.com), 5. Masimo Radius PPG (masimo.com). Advantages: Specific cardio-pulmonary focus and continuous monitoring platform. Disadvantages: Enterprise/device-led model may have longer sales cycles vs. more agile software platforms; limited self-serve appeal as noted on Product Hunt.

Upgrade Pro to unlock full AI analysis